Agenda
8:00am PT - Panel
8:45am PT - Q&A
2020 has been an unpredictable year with COVID-19, but cell and gene therapy innovators are ready. Please join us for an interactive, virtual panel discussion with some of the leading voices in advanced therapies, as well as champions of excellence through systems, data, and collaboration.
Tuesday, July 21st | 8am PT / 11am ET
8:00am PT - Panel
8:45am PT - Q&A
Vineti, CEO & Co-Founder
Before co-founding Vineti, Amy focused on healthcare new business creation for GE Ventures/healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was co-founder and Executive Director of Proposition 71, California’s $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Amy holds an MBA and MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute. Amy also serves as a member of the Board of Directors for the ARM Foundation for Cell and Gene Medicine.
Optum, SVP, Provider Technology Services
John leads the Provider Technology Services practice within Optum Advisory Services. He plays a pivotal role leading EHR implementation and optimization, population health/value-based operations efforts and IT strategy.
Prior to consulting, he practiced internal medicine for 14 years. His focus was ambulatory chronic disease management and inpatient critical care.
John Kontor’s unique perspective comes from his experience serving as an executive in multiple roles at IDNs. These include chief medical information officer, vice president of medical affairs and medical director of an employed physician network.
John received his Bachelor of Arts from Boston University in health policy and earned his Doctor of Medicine from the University of Florida in Gainesville.
FerGene, SVP, Technical Operations
Peter serves as senior vice president of technical operations at FerGene where he oversees manufacturing, process and analytical development, quality and supply chain for the company.
Prior to joining the company Peter served as the vice president of patient operations with bluebird bio, a biotech company in Cambridge. In this role, Peter had responsibility for the personalized manufacturing & Centers of Excellence (COE) engagement activities including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments.
During his tenure at bluebird bio, Peter also served as the program leader for Zynteglo®, which was approved by the European Medicines Agency (EMA) for patients with transfusion dependent thalassemia. As program lead, he was responsible for the program development team, which was comprised of cross functional representatives spanning research, development, and commercial.
Prior to bluebird bio, Peter served as senior director, global technical operations at Dendreon where he managed the US and EU manufacturing operations and supply chain, including contract manufacturers, external testing sites, and the apheresis network for those regions.
Earlier in his career, Peter had leadership positions within the quality function at ZymoGenetics, a monoclonal antibody organization that was acquired by BMS in 2011.
PACT Pharma, President & COO
Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Most recently, he served as Executive Vice President, Technical Operations at Kite, a Gilead Company, since March of 2016. During this time Mr. Moore was responsible for overseeing the process development, manufacturing, quality and supply chain for the launch of Yescarta®, one of the first CAR T therapies to be developed, manufactured and commercialized, as well as advancement of the Kite pipeline. In addition, Mr. Moore globally expanded the biopharmaceutical operations to serve and support the US, EU, as well as key partners in Asia.
Prior to Kite, Mr. Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech’s Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and serves as a Board member for Cerus. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.
Canaan, General Partner, Moderator
Nina Kjellson invests in biopharma and digital health companies that serve unmet therapeutic and access needs. As a leader of Canaan’s Women of Venture program, Nina is a vocal advocate for women entrepreneurs and investors. She serves as a mentor to Blueprint Health and Springboard Life Sciences and on the boards of Essential Access Health, the California Leadership Council for The Nature Conservancy and the Oliver Wyman Health Innovation Center. Nina is also a 2018 Aspen Institute Health Innovators Fellow. Previously, Nina was a General Partner at Interwest Partners. She holds a B.A. in human biology from Stanford University.